Event to include demos and training for distributors and end-users of Company’s products
Salt Lake City, Utah – August 21, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will host the 2nd Semiannual Co-Diagnostics Distributor Conference on September 10-12, 2019 at the Company’s headquarters in Salt Lake City, Utah.
Conference attendees consist of current and potential distributors of the Company’s products, representatives from government and environmental testing institutions, and private laboratory customers, attending from countries across Asia, Africa, and the Latin American/Caribbean region. Sessions and product demonstrations will involve hands-on laboratory training and will showcase the advantages of the CoPrimer™ technology in varying applications. The Conference agenda also includes new product updates and an introduction to the Company’s custom next-gen sequencing (NGS) library prep, for which a provisional patent was filed earlier this year.
Any distributors or organizations interested in attending should request an invitation from Cameron Gundry, Co-Diagnostics Head of Commercialization (LATAM/EUR), at: c.gundry[at]codiagnostics.com.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, (ix) benefits in research and worldwide accessibility of the CoPrimer™ technology and its cost-saving and scientific advantages and (x) statements regarding the intended use of proceeds. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Company Sales Contact:
Co-Diagnostics Head of International Sales